Clinical Trial Update: The Role of the Tumor Molecular Profile (CMS), UGT1A1 Genotype and Beta-glucuronidase Activity of the Intestinal Microbiota for Treatment Efficiency, Toxicity, Survival and Quality of Life in Patients With Metastatic or Unresectable Colorectal Cancer During Irinotecan-based Systemic Treatment

View source ↗

Summary

A clinical trial is examining how tumor molecular profile (CMS), UGT1A1 genotype, and intestinal beta-glucuronidase activity influence treatment efficacy, toxic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Maastricht University Medical Center | Conditions: Colorectal Neoplasms | Status: RECRUITING